CYAD News and Press, Celyad SA From 06/05/20

Celyad Reports Positive Update on Non Gene Edited Allogeneic CAR-T Therapy Celyad ( CYAD ) announced update for its Phase 1 clinical trial alloSHRINK. The trial aims to assess the potential of its lead drug candidate CYAD-101 for patients suffering from metastatic colorectal cancer. It e...

Ultra-thinly traded micro cap Celyad ( CYAD +9.0% ) is up on more than double normal volume, albeit on turnover of only 39K shares, in reaction to updated data from a Phase 1 clinical trial, alloSHRINK , evaluating CYAD-101 in patients with metastatic colorectal cancer (mCRC). The resul...

First-in-class TIM-based non-gene edited allogeneic CAR-T candidate, CYAD-101, shows encouraging clinical activity with no evidence of graft-versus-host disease in relapsed/refractory metastatic colorectal cancer patients Two patients achieved a confirmed partial response and nine pat...

MONT-SAINT-GUIBERT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the company plans to participate in the following virtu...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Celyad (NASDAQ: CYAD ): Q1 Net cash burn of €5.5M More news on: Celyad SA, Earnings news and commentary, Healthcare stocks news, , Read more ...

MONT-SAINT-GUIBERT, Belgium, May 07, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on operational developments for the first quarter en...

MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that Dr. Maria Koehler and Mr. Dominic Piscitelli have b...

Two accepted abstracts will be presented virtually in a prerecorded poster presentation MONT-SAINT-GUIBERT, Belgium, April 30, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...